# Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis

> **NCT02324972** · PHASE2 · COMPLETED · sponsor: **Aquinox Pharmaceuticals (Canada) Inc.** · enrollment: 54 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** AQX-1125
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02324972
- **Lead sponsor:** Aquinox Pharmaceuticals (Canada) Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2015-11
- **Final completion:** 2015-12
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2018-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02324972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02324972, "Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02324972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*